Lincoln Pharmaceuticals is currently trading at Rs. 152.70, up by 7.25 points or 4.98% from its previous closing of Rs. 145.45 on the BSE.
The scrip opened at Rs. 150.00 and has touched a high and low of Rs. 152.70 and Rs. 146.25 respectively. So far 77827 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 220.00 on 28-Jan-2020 and a 52 week low of Rs. 85.50 on 19-Mar-2020.
Last one week high and low of the scrip stood at Rs. 152.70 and Rs. 131.00 respectively. The current market cap of the company is Rs. 305.40 crore.
The promoters holding in the company stood at 32.40%, while Institutions and Non-Institutions held 0.28% and 67.33% respectively.
Lincoln Pharmaceuticals has received approval to manufacture Hydroxychloroquine (HCQ) among other critical drugs to fight COVID 19. The company has received approval from Food & Drug Control Administration, Gujarat to manufacture varied dosages of Hydroxychloroquine Tablets and Hydroxychloroquine Sulfate Tablets among others at its plant in Khatraj in Ahmedabad.
After necessary approval from Directorate General of Foreign Trade (DGFT) company will be able to export these products. Food & Drug Control Administration, Gujarat approved manufacture of Hydroxychloroquine Sulfate Tablets USP in 200 MG, 300 MG and 400 MG dosages and Hydroxychloroquine Tablets IP in 200 MG, 300 MG and 400 MG dosages respectively from company’s Khatraj facility.
Lincoln Pharmaceuticals is engaged in the manufacture and marketing of affordable therapeutic products. The product range of the company includes Tablets, Capsules, Injectable, Syrups and Ointments.
